Clinical Trial: Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06820567) titled 'Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD' on Feb. 06.

Brief Summary: the effect of Dapagliflozin on erythropoiesis, iron metabolism and inflammatory markers in CKD with Type 2 DM-Compare between effect of placebo and dapagliflozin on erythropoiesis, iron metabolism and inflammation markers in CKD with Type 2 DM.

Study Start Date: March 01

Study Type: INTERVENTIONAL

Condition: Chronic Kidney Diseases Diabetes Type 2

Intervention: DRUG: Dapagliflozin (DAPA)

patient will recive dapagliflozin for 24 week to improvement of eGFR on CKD patients

DRUG: ...